Experience with other CDK4/6 inhibitors suggests that promising efficacy signals such as these might be enhanced through rational combinations with AIs, fulvestrant, or antitumor agents with different targets/mechanisms of action (including radiation therapy) suited to the tumor of interest [3,8,29,30,31]. The gene discussed is CDK4; the disease is neoplasm.